Clinical significance of detection of bcr-abl mRNA in chronic myeloid leukemia

( views:153, downloads:0 )
Author:
L(U) Xiao-dong(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
FAN Rui-hua(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
HU Jie-ying(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
XU Ben-ling(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
ZHANG Xu-hua(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
SONG Yun-feng(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
SONG Yong-ping(Central laboratory of Henan Tumor Hospital, Zhengzhou 450008, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 20, Issue 06, 2011
DOI:
10.3760/cma.j.issn.1009-9921.2011.06.003
Key Word:
Leukemia,myeloid,chronic;Real-time polymerase chain reaction;bcr-abl mRNA

Abstract: Objective To evaluate significance of the quantification of bcr-abl mRNA in diagnosis and therapy of chronic myeloid leukemia (CML),essentiality significance for monitoring minimal residual disease. Methods Bcr-abl mRNA of 518 CML patients were detected using real-time PCR. Results Expression of bcr-abl mRNA was gradually increased among blastic phase (BP) (12.6 %),accelerated phase (AP) (25.4 %) and chronic phase (CP) (57.2 %) (P<0.05). Quantification of bcr-abl mRNA was cut down gradually after allotransplantation in the patients and becomes normal after treatment for 6 months. But quantification of bcr-abl mRNA inpatients treated with imatinib mesylate became normal after 12 months. Conclusion Real-time PCR was reliable and can be used for diagnosis,monitoring the treatment outcome,detecting the minimal residual disease,and predicting blast crisis.

  • [1]张之南.血液病诊断及治疗标准.2版.北京:科学出版社,1998:1931.
  • [2]Ross DM,Watkins DB,Hughes TP,et al.Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia:implications for defining sensitivity in minimal residual disease.Clin Chem,2008,54:1568-1571.
  • [3]Elmaagacli AH,Beelen DW,Opalka B,et al.The amount of BCRABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.Ann Hematol,2000,79:424-431.
  • [4]Paschka P,Muller MC,Merx K,et al.Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha.Low levels of residual disease are associated with continuous remission.Leukemia,2003,17:1687-1694.
  • [5]Radich JP,Gehly G,Gooley T,et al.Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia:results and implication in 346 patients.Blood,1995,85:2632-2638.
  • [6]Cross NC,Hughes TP,Feng L,et al.Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase:correlations with acute graft-vereus-host disease and relapse.Br J Haematol,1993,84:67-74.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn